Skip to main content
. 2018 May 3;45(10):1781–1794. doi: 10.1007/s00259-018-4029-9

Fig. 11.

Fig. 11

Theranostic trial of somatostatin antagonists 68Ga-OPS201 and 177Lu-OPS201 in well-differentiated neuroendocrine tumours (NET), revealing high safety and excellent response rates even after only one cycle of therapy with 177Lu-OPS201 [41]